...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Acta oncologica. >Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis
【24h】

Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis

机译：Pazopanib在晚期血管肉瘤中：EORTC软组织和骨肉瘤组（STBSG）回顾性分析

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Pazopanib is a multitargeted tyrosine kinase inhibitor approved for the treatment of patients with selective subtypes of advanced soft tissue sarcoma (STS) who have previously received standard chemotherapy including anthracyclines. Data on the efficacy in vascular sarcomas are limited. The main objective of this study was to investigate the activity of pazopanib in vascular sarcomas. Patients and methods: A retrospective study of patients with advanced vascular sarcomas, including angiosarcoma (AS), epithelioid hemangioendothelioma (HE) and intimal sarcoma (IS) treated with pazopanib in real life practice at EORTC centers as well as patients treated within the EORTC phase II and III clinical trials (62043/62072) was performed. Patient and tumor characteristics were collected. Response was assessed according to RECIST 1.1. and survival analysis was performed. Results: Fifty-two patients were identified, 40 (76.9%), 10 (19.2%) and two (3.8%) with AS, HE and IS, respectively. The response rate was eight (20%), two (20%) and two (100%) in the AS, HE and IS subtypes, respectively. There was no significant difference in response rate between cutaneous and non-cutaneous AS and similarly between radiation-associated and non-radiation-associated AS. Median progression-free survival (PFS) and median overall survival (OS; from commencing pazopanib) were three months (95% Cl 2.1-4.4) and 9.9 months (95% Cl 6.5-11.3) in AS, respectively.
机译：背景：Pazopanib是一种批准用于治疗先前接受过包括蒽环类药物的标准化疗的先进软组织Sarcoma（STS）的选择性亚型患者的多元酪氨酸激酶抑制剂。关于血管肉瘤效力的数据有限。本研究的主要目的是研究Pazopanib在血管肉瘤中的活性。患者及方法：对血管肉瘤的患者的回顾性研究，包括昂皮血症（AS），上皮血管血管瘤（他）和Intimal Sarcoma（IS）在EORTC中心的现实生活实践中与Pazopanib进行治疗，以及在ETTC阶段治疗的患者II和III临床试验（62043/62072）进行。收集患者和肿瘤特性。根据Recist 1.1评估响应。并进行存活分析。结果：鉴定了52名患者，40例（76.9％），10（19.2％）和两（3.8％），分别为他，是他的。响应率分别为八（20％），两（20％）和两（100％），分别为亚型。皮肤和非皮肤之间的响应速率没有显着差异，并且在辐射相关和非辐射相关的辐射相关和相关的辐射相关的响应率之间。中位进展的生存（PFS）和中位数整体存活（OS;从开始的Pazopanib）分别为3个月（95％Cl 2.1-4.4）和9.9个月（95％Cl 6.5-11.3）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号